The proposed transaction would see the combined entity trade on the Nasdaq under the ticker symbol IEAI, led by current Infinite Epigenetics CEO Dr. Matthew Dawson. Under the terms, existing Nano shareholders will retain a minority stake, valued at a 20% premium over the company’s estimated net cash at the time of closing. Both parties anticipate the new firm will hold more than $400 million in cash reserves.

This move concludes a strategic review initiated by Nano CEO David Stehlin, who previously signaled that the company was scouting for high-growth opportunities after streamlining its operations and pausing share buybacks. By integrating with Infinite Epigenetics, Nano aims to leverage its public platform and capital to scale the startup’s proprietary technology, which utilizes artificial intelligence to identify health risks through epigenetic DNA markers.